LILRB2(Polzastobart Biosimilar Antibody)重組單克隆抗體是一款專為科研用途開(kāi)發(fā)的高特異性生物試劑，其靶點(diǎn)為白細(xì)胞免疫球蛋白樣受體B2（LILRB2）。該受體屬于免疫球蛋白超家族成員，廣泛表達(dá)于免疫細(xì)胞表面，在免疫調(diào)節(jié)、炎癥反應(yīng)及腫瘤微環(huán)境調(diào)控中發(fā)揮關(guān)鍵作用。 本產(chǎn)品通過(guò)重組DNA技術(shù)在哺乳動(dòng)物細(xì)胞中表達(dá)，經(jīng)多步純化工藝獲得高純度抗體，確保批次間一致性和實(shí)驗(yàn)結(jié)果的可靠性。其抗原結(jié)合片段（Fab）可精準(zhǔn)識(shí)別LILRB2胞外結(jié)構(gòu)域，通過(guò)特異性結(jié)合實(shí)現(xiàn)對(duì)受體功能的調(diào)控研究。在實(shí)驗(yàn)應(yīng)用中，該抗體可用于檢測(cè)細(xì)胞表面LILRB2的表達(dá)水平，分析組織樣本中的受體分布，以及探究蛋白質(zhì)相互作用等機(jī)制研究。 作為科研工具，LILRB2重組單克隆抗體為揭示免疫檢查點(diǎn)分子的生理病理功能提供了有力支持。研究人員可利用該抗體探索LILRB2在自身免疫性疾病、腫瘤免疫逃逸及感染性疾病中的作用機(jī)制，為開(kāi)發(fā)新型治療策略提供理論依據(jù)。產(chǎn)品嚴(yán)格按照科研試劑標(biāo)準(zhǔn)生產(chǎn)，僅用于實(shí)驗(yàn)室研究，不涉及臨床診斷或治療用途。 該抗體的研發(fā)與應(yīng)用有助于推動(dòng)免疫學(xué)及相關(guān)領(lǐng)域的基礎(chǔ)研究，為深入理解免疫調(diào)節(jié)網(wǎng)絡(luò)、發(fā)現(xiàn)潛在藥物靶點(diǎn)奠定實(shí)驗(yàn)基礎(chǔ)。

Q8N423

JTX8064 research-grade biosimilar; JTX-8064 research-grade biosimilar ;LILRB2 antibody; ILT4 antibody; LIR2 antibody; MIR10 antibody; Leukocyte immunoglobulin-like receptor subfamily B member 2 antibody; LIR-2 antibody; Leukocyte immunoglobulin-like receptor 2 antibody; CD85 antigen-like family member D antibody; Immunoglobulin-like transcript 4 antibody; ILT-4 antibody; Monocyte/macrophage immunoglobulin-like receptor 10 antibody; MIR-10 antibody; CD antigen CD85d antibody

Human

Recombinant Human LILRB2 protein

Homo sapiens (Human)

Non-conjugated

Monoclonal

It differs from different batches. Please contact us to confirm it.

0.01M PBS，pH7.4

Liquid

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

3-4 weeks

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.